Overview

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Status:
Completed

Trial end date:
2013-07-15

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.

Phase:

Phase 2

Details

Lead Sponsor:

Shire

Treatments:

Guanfacine